Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-08-23
2005-08-23
Stucker, Jeffrey (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S235100, C435S236000, C435S320100
Reexamination Certificate
active
06933377
ABSTRACT:
The present invention relates to prophylactic and therapeutic acquired immunodeficiency syndrome vaccines. In particular, the present invention provides methods and compositions utilizing recombinant HIV-1, HIV-2 and/or SIV genes or gene products in safe vaccination approaches.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis
patent: 4683202 (1987-07-01), Mullis
patent: 4965188 (1990-10-01), Mullis
Rifkin et al. “A single amino-acid change between the antigenically different extracellular serine proteases V2 and B2 fromDichelobacter nodosus”, Gene, vol. 167 (1995), pp. 279-283.
Abaza et al. “Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization”, Journal of Protein Chemistry, vol. 11, No. 5 (1992), pp 433-444.
Cruse et al. Illustrated Dictionary of Immunology (Boca Raton, FL, CRC Press, Inc., 1995), p. 309. QR180.4.C78.
Paul, Fundamental Immunology, (Philadelphia & New York, Lippincott-Raven Publishers, 1993), pp. 250 and 1311-1312. QR181.F84.
Aldovini and Young, “Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus,”J. Virol.,64:1920-1926 [1990].
Ausubel et al.,Current Protocols in Molecular Biology,Greene Publishing Associates and Wiley Interscience, N.Y. [1989] copyright pages only.
Baba et al., “Live attenuated, multiply deleted simian immunodeficiency virus cases AIDS in infant and adult macaques,”Nat. Med.,5:194-203 [1999].
Benson et al., “Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIVmac251: dependence on route of challenge exposure,”J. Virol.,72:4170-4182 [1998].
Bernstein et al., “Oligomerization of the hydrophobic heptad repeat of gp41”,J. Virol.,69:2745-2750 [1995].
Cheng et al., “Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant,”J. Virol.,66:6721-6727 [1992].
Clavel and Orenstein, “A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology,”J. Virol.,64:5230-5234 [1990].
Collman et al., “An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1,”J. Virol.,66:7517-7521 [1992].
Emerman and Malim, “HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology,”Science,280:1880-1884 [1998].
Ferco et al., “Hyperattenuated recombinant influenza a virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice,”J. Virol.,75:8899-8908 [2001].
Franchini et al., “Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses,”Nature,328:539-543 [1987].
Gailer et al., “The yellow fever 17D vaccine virus: molecular basis of viral attenuation and its use as an expression vector,”Brazilian J. Med. Biol. Res.,30:157-168 [1997] abstract only.
Galli et al., “Th1 and Th2 responses, HIV-1 coreceptors, and HIV-1 infections,”J. Biol. Regul. Homeost. Agents,15:308-313 [2001] abstract only.
Gallo et al., “HIV/HTLV gene nomenclature,”Nature,333:504 [1988].
Gorse et al., “HIV type 1 vaccine-induced t cell memory and cytotoxic t lymphocyte responses in HIV type 1-uninfected volunteers,”AIDS Res. Hum. Retroviruses,17:1175-1189 [2001].
Gottlinger et al., “Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1,”Proc. Natl. Acad. Sci., USA,86:5781-5785 [1989].
Graham et al., “Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp)120,”Ann. Intern. Med.,125:270-279 [1996].
Hu et al., “The emerging genetic diversity of HIV: the importance of global surveillance for diagnostics, research, and prevention,”JAMA,275:210-216 [1996].
Jacks et al., “Characterization of ribosomal frameshifting in HIV-1 gag-pol expression,”Nature,331:280-283 [1988].
Kobayashi et al., “Immunostimulatory DNA prepriming: a novel approach for prolonged Th1-biased immunity,”Cell Immunol.,198:69-75 [1999].
Korber et al., “Limitations of a molecular clock applied to considerations of the origin of HIV-1,”Science,280:1868-1871 [1998].
Kumar et al., “A recombinant BCG vaccine generates a Th1-like response and inhibits IgE synthesis in BALB/c mice,”Immunol.,97:515-521 [1999].
Lever et al., “Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 virus RNA into virions,”J. Virol.,63:4085-4087 [1989].
Levy, “Pathogenesis of human Immunodeficiency virus infection,”Microbiol. Rev.,57:183-289 [1993] abstract only.
Lewis et al., “Identification of a cis-acting element in human immunodeficiency virus type 2 (HIV-2) that is responsive to the HIV-1 rev and human T-cell leukemia virus types I and II rex proteins,”J. Virol.,64:1690-1697 [1990].
Mellors et al., “Plasma viral load and CD4+lymphocytes markers of HIV-1 infection,”Ann. Intern. Med.,126:946-954 [1997].
Miller et al., “Rhesus macaquespreviously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239,”J. Virol.,71:1911-1921 [1997].
Monath et al., “Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates,”Vaccine,17:1869-1882 [1999].
Mooij and Heeney, “Rational development of prophylactic HIV vaccines based on structural and regulatory proteins,”Vaccine,20:304-321 [2002].
Muesing et al., “Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus,”Nature,313:450-458 [1985].
Pang et al., “High level of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients,”Nature,343:85-89 [1990].
Perelson et al., “HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time,”Science,271:1582-1586 [1996].
Purvis et al., “HIV type 1 Tat protein induces apoptosis and death in Jurkat cells,”AIDS Res. Hum. Retroviruses,11:443-450 [1995].
Pushko et al., “Replicon-helper systems from attenuated venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo,”Virology,239:389-401 [1997].
Regier and Destrosiers, “The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus,”AIDS Res. Hum. Retro.,6:1221-1232 [1990].
Reinhardt et al., “Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17d: a model of human flavivirus infection,”J. Med. Virol.,56:159-167 [1998].
Rose et al., “An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants,”Cell,106:539-549 [2001].
Sambrook et al.,Molecular Cloning: A Laboratory Manual,Cold Spring Harbor Laboratory, N.Y. [1989].
Sato et al., “Immunostimulatory DNA sequences necessary for effective intradermal gene immunization,”Science,273:352-354 [1996].
Schnell, “Viral vectors as potential HIV-1 vaccines,”FEMS Microbiol. Lett.,200:123-129 [2001].
Smerdou and Liljestrom, “Two-helper RNA system for production of recombinant Semliki forest virus particles,”J. Virol.,73:1092-1098 [1999].
Sukwit et al., “Flow cytometric dete
Medlen & Carroll LLP
Stucker Jeffrey
LandOfFree
Compositions comprising multiple immunodeficiency virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions comprising multiple immunodeficiency virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions comprising multiple immunodeficiency virus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3462917